Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy

Ha Na Woo1*, Hye Kyung Chung2*, Eun Jin Ju1, Joohee Jung1,3, Hye-Won Kang4, Sa-Won Lee4, Min-Hyo Seo4, Jin Seong Lee5, Jung Shin Lee1,6, Heon Joo Park7, Si Yeol Song1,8, Seong-Yun Jeong1, Eun Kyung Choi1,2,81Institute for Innovative Cancer Research, 2Center for Development and Commercialization of A...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Woo HN, Chung HK, Ju EJ, Jung J, Kang HW, Lee SW, Seo MH, Lee JS, Park HJ, Song SY, Jeong SY, Choi EK
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2012
Materias:
Acceso en línea:https://doaj.org/article/7e101255baee40b5b2876380e6038d5c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:7e101255baee40b5b2876380e6038d5c
record_format dspace
spelling oai:doaj.org-article:7e101255baee40b5b2876380e6038d5c2021-12-02T01:19:51ZPreclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy1176-91141178-2013https://doaj.org/article/7e101255baee40b5b2876380e6038d5c2012-04-01T00:00:00Zhttp://www.dovepress.com/preclinical-evaluation-of-injectable-sirolimus-formulated-with-polymer-a9776https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Ha Na Woo1*, Hye Kyung Chung2*, Eun Jin Ju1, Joohee Jung1,3, Hye-Won Kang4, Sa-Won Lee4, Min-Hyo Seo4, Jin Seong Lee5, Jung Shin Lee1,6, Heon Joo Park7, Si Yeol Song1,8, Seong-Yun Jeong1, Eun Kyung Choi1,2,81Institute for Innovative Cancer Research, 2Center for Development and Commercialization of Anti-cancer Therapeutics, Asan Medical Center, Seoul, 3College of Pharmacy, Duksung Women's University, Seoul, 4Department of Parenteral Delivery Program, Samyang Pharmaceuticals R&D, Daejeon, 5Department of Radiology and Research Institute of Radiology, 6Department of Internal Medicine, Asan Medical Center, Seoul, 7Department of Microbiology, College of Medicine, Inha University, Inchon, 8Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea*These authors contributed equally to this studyAbstract: Nanoparticles are useful delivery vehicles for promising drug candidates that face obstacles for clinical applicability. Sirolimus, an inhibitor of mammalian target of rapamycin has gained attention for targeted anticancer therapy, but its clinical application has been limited by its poor solubility. This study was designed to enhance the feasibility of sirolimus for human cancer treatment. Polymeric nanoparticle (PNP)–sirolimus was developed as an injectable formulation and has been characterized by transmission electron microscopy and dynamic light scattering. Pharmacokinetic analysis revealed that PNP–sirolimus has prolonged circulation in the blood. In addition, PNP–sirolimus preserved the in vitro killing effect of free sirolimus against cancer cells, and intravenous administration displayed its potent in vivo anticancer efficacy in xenograft tumor mice. In addition, PNP–sirolimus enhanced the radiotherapeutic efficacy of sirolimus both in vitro and in vivo. Clinical application of PNP–sirolimus is a promising strategy for human cancer treatment.Keywords: sirolimus, polymeric nanoparticle, anticancer, radiotherapyWoo HNChung HKJu EJJung JKang HWLee SWSeo MHLee JSLee JSPark HJSong SYJeong SYChoi EKDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2012, Iss default, Pp 2197-3008 (2012)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Woo HN
Chung HK
Ju EJ
Jung J
Kang HW
Lee SW
Seo MH
Lee JS
Lee JS
Park HJ
Song SY
Jeong SY
Choi EK
Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy
description Ha Na Woo1*, Hye Kyung Chung2*, Eun Jin Ju1, Joohee Jung1,3, Hye-Won Kang4, Sa-Won Lee4, Min-Hyo Seo4, Jin Seong Lee5, Jung Shin Lee1,6, Heon Joo Park7, Si Yeol Song1,8, Seong-Yun Jeong1, Eun Kyung Choi1,2,81Institute for Innovative Cancer Research, 2Center for Development and Commercialization of Anti-cancer Therapeutics, Asan Medical Center, Seoul, 3College of Pharmacy, Duksung Women's University, Seoul, 4Department of Parenteral Delivery Program, Samyang Pharmaceuticals R&D, Daejeon, 5Department of Radiology and Research Institute of Radiology, 6Department of Internal Medicine, Asan Medical Center, Seoul, 7Department of Microbiology, College of Medicine, Inha University, Inchon, 8Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea*These authors contributed equally to this studyAbstract: Nanoparticles are useful delivery vehicles for promising drug candidates that face obstacles for clinical applicability. Sirolimus, an inhibitor of mammalian target of rapamycin has gained attention for targeted anticancer therapy, but its clinical application has been limited by its poor solubility. This study was designed to enhance the feasibility of sirolimus for human cancer treatment. Polymeric nanoparticle (PNP)–sirolimus was developed as an injectable formulation and has been characterized by transmission electron microscopy and dynamic light scattering. Pharmacokinetic analysis revealed that PNP–sirolimus has prolonged circulation in the blood. In addition, PNP–sirolimus preserved the in vitro killing effect of free sirolimus against cancer cells, and intravenous administration displayed its potent in vivo anticancer efficacy in xenograft tumor mice. In addition, PNP–sirolimus enhanced the radiotherapeutic efficacy of sirolimus both in vitro and in vivo. Clinical application of PNP–sirolimus is a promising strategy for human cancer treatment.Keywords: sirolimus, polymeric nanoparticle, anticancer, radiotherapy
format article
author Woo HN
Chung HK
Ju EJ
Jung J
Kang HW
Lee SW
Seo MH
Lee JS
Lee JS
Park HJ
Song SY
Jeong SY
Choi EK
author_facet Woo HN
Chung HK
Ju EJ
Jung J
Kang HW
Lee SW
Seo MH
Lee JS
Lee JS
Park HJ
Song SY
Jeong SY
Choi EK
author_sort Woo HN
title Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy
title_short Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy
title_full Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy
title_fullStr Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy
title_full_unstemmed Preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy
title_sort preclinical evaluation of injectable sirolimus formulated with polymeric nanoparticle for cancer therapy
publisher Dove Medical Press
publishDate 2012
url https://doaj.org/article/7e101255baee40b5b2876380e6038d5c
work_keys_str_mv AT woohn preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT chunghk preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT juej preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT jungj preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT kanghw preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT leesw preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT seomh preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT leejs preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT leejs preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT parkhj preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT songsy preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT jeongsy preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
AT choiek preclinicalevaluationofinjectablesirolimusformulatedwithpolymericnanoparticleforcancertherapy
_version_ 1718403146231840768